Comparative Pharmacology
Head-to-head clinical analysis: QUADRAMET versus XENOVIEW.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUADRAMET versus XENOVIEW.
QUADRAMET vs XENOVIEW
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Samarium Sm 153 lexidronam is a radiolabeled agent that localizes to areas of osteoblastic bone activity. The samarium-153 isotope emits beta particles and gamma photons, delivering radiation to the bone and surrounding tissues. This results in the destruction of malignant cells in bone metastases.
Xenoview is a paramagnetic contrast agent for MRI that enhances T1 relaxation by shortening the longitudinal relaxation time of water protons in tissues where it accumulates, thereby increasing signal intensity on T1-weighted images.
1.0 mCi/kg (37 MBq/kg) intravenously as a single dose.
Not applicable (diagnostic agent, not therapeutic); refer to imaging protocol.
None Documented
None Documented
Terminal half-life: 6–8 hours (prolonged in renal impairment; may exceed 20 hours in CrCl <30 mL/min).
Terminal elimination half-life is 3-5 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as other minor metabolites.
Primarily renal excretion (60-70% unchanged drug), with 20-25% biliary/fecal elimination.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical